touchPODCAST

The complement system in NMOSD and MG: A target for therapeutic benefit?

touchPANEL DISCUSSION for touchOPHTHALMOLOGY

Listen to a panel of leading experts discuss  the evidence for complement involvement in the pathogenesis of neuromyelitis optica spectrum disorder and myasthenia gravis, review the markers of complement activation, and highlight the implications of the latest data for complement therapeutics for practice.

The experts

• Prof. Said Beydoun, Keck School of Medicine of USC, Los Angeles, CA, USA
• Prof. Heinz Wiendl, University Hospital Münster, Münster, Germany
• Dr Pushpa Narayanaswami, Beth Israel Deaconess Medical Center, Boston, MA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Alexion Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

To view this activity in full and to access the downloadable materials please visit: touchOPHTHALMOLOGY

The complement system in NMOSD and MG: A target for therapeutic benefit?

touchPANEL DISCUSSION for touchIMMUNOLOGY

Listen to a panel of leading experts discuss  the evidence for complement involvement in the pathogenesis of neuromyelitis optica spectrum disorder and myasthenia gravis, review the markers of complement activation, and highlight the implications of the latest data for complement therapeutics for practice.

The experts

• Prof. Said Beydoun, Keck School of Medicine of USC, Los Angeles, CA, USA
• Prof. Heinz Wiendl, University Hospital Münster, Münster, Germany
• Dr Pushpa Narayanaswami, Beth Israel Deaconess Medical Center, Boston, MA, USA

This touchPODCAST is for HCPs only.

An independent medical education grant from Alexion Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchIMMUNOLOGY

The complement system in NMOSD and MG: A target for therapeutic benefit

touchPANEL DISCUSSION for touchNEUROLOGY

Listen to a panel of leading experts discuss  the evidence for complement involvement in the pathogenesis of neuromyelitis optica spectrum disorder and myasthenia gravis, review the markers of complement activation, and highlight the implications of the latest data for complement therapeutics for practice.

The experts

• Prof. Said Beydoun, Keck School of Medicine of USC, Los Angeles, CA, USA
• Prof. Heinz Wiendl, University Hospital Münster, Münster, Germany
• Dr Pushpa Narayanaswami, Beth Israel Deaconess Medical Center, Boston, MA, USA

This touchPODCAST is for HCPs only.

An independent medical education grant from Alexion Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchNEUROLOGY

Contemporary insights on sickle cell disease complications and recent advances in therapy

touchPANEL DISCUSSION for touchRESPIRATORY

Listen to three expert haematologists discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

The experts

• Prof. Biree Andemariam, Farmington, CT, USA
• Prof. Modupe Idowu, Houston, TX, USA
• Prof. Mark C Walters, Oakland, CA, USA

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Agios Pharmaceuticals Inc., Pfizer and Vertex Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information please visit our website: touchRESPIRATORY

Contemporary insights on sickle cell disease complications and recent advances in therapy

touchPANEL DISCUSSION for touchNEUROLOGY

Listen to three expert haematologists discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

The experts

• Prof. Biree Andemariam, Farmington, CT, USA;
• Prof. Modupe Idowu, Houston, TX, USA;
• Prof. Mark C Walters, Oakland, CA, USA;

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Agios Pharmaceuticals Inc., Pfizer and Vertex Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information please visit our website: touchNEUROLOGY

Contemporary insights on sickle cell disease complications and recent advances in therapy

touchPANEL DISCUSSION for touchCARDIO

Listen to three expert haematologists discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

The experts

• Prof. Biree Andemariam, Farmington, CT, USA;
• Prof. Modupe Idowu, Houston, TX, USA;
• Prof. Mark C Walters, Oakland, CA, USA;

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Agios Pharmaceuticals Inc., Pfizer and Vertex Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information please visit our website: touchCARDIO

Contemporary insights on sickle cell disease complications and recent advances in therapy

touchPANEL DISCUSSION for touchHAEMATOLOGY

Listen to three expert haematologists discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

The experts

• Prof. Biree Andemariam, Farmington, CT, USA;
• Prof. Modupe Idowu, Houston, TX, USA;
• Prof. Mark C Walters, Oakland, CA, USA;

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Agios Pharmaceuticals Inc., Pfizer and Vertex Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information please visit our website: touchHAEMATOLOGY

New and emerging agents in HER2-negative metastatic breast cancer Implications for current and future practice

touchPANEL DISCUSSION for touchONCOLOGY

Listen to three breast cancer experts discuss the expanding targeted treatment options for HER2-negative metastatic breast cancer, with a focus on approved and emerging antibody drug conjugates and considerations for their use in clinical practice. 

The experts

• Prof. Giuseppe Curigliano, University of Milan, Milan, Italy
• Prof. Hope Rugo, University of California, San Francisco, CA, USA
• Prof. Peter Schmid, Barts Cancer Institute, London, UK

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/new-and-emerging-agents-in-her2negative-mbc 

DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchCARDIOLOGY

touchEXPERT OPINIONS for touchCARDIOLOGY

Leading experts share their insights on the impact of intracerebral haemorrhage (ICH) in patients receiving direct oral anticoagulants (DOACs), DOAC-ICH reversal agents and optimizing treatment outcomes.

The experts:

• Prof. Hanne Christensen, University of Copenhagen, Denmark
• Prof. Thorsten Steiner, The Clinical Centre in Frankfurt Höchst, Frankfurt, Germany
• Dr Truman Milling, The University of Texas at Austin, TX, USA

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit
www.touchcardio.com

DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchNEUROLOGY

touchEXPERT OPINIONS for touchNEUROLOGY

Leading experts share their insights on the impact of intracerebral haemorrhage (ICH) in patients receiving direct oral anticoagulants (DOACs), DOAC-ICH reversal agents and optimizing treatment outcomes.

The experts:

• Prof. Hanne Christensen, University of Copenhagen, Denmark
• Prof. Thorsten Steiner, The Clinical Centre in Frankfurt Höchst, Frankfurt, Germany
• Dr Truman Milling, The University of Texas at Austin, TX, USA

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit:
www.touchneurology.com